ConductScience.org, home

Paper19684847

Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results.

Güler S and 8 others. Arch Drug Inf, 2009. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results. Papers, record 19684847. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19684847

Download JSON
Disease
type 2 diabetes mellitus613 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results.
PubMed
Journal
Arch Drug Inf
PubMed
Year
2009
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.17
iCite
Revised in PubMed
2021-10-20
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Güler SSerdar
2Sharma SKSurendra Kumar
3Almustafa MMajeed
4Kim CHChong Hwa
5Azar SSami
6Danciulescu RRucsandra
7Shestakova MMarina
8Khutsoane DDuma
9Bech OMOle Molskov

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01536600Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 DiabetesResults

Source ClinicalTrials.gov

Download CSV of trials

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19742976
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet1998https://conductscience.org/library/papers/9742976PubMed
211815505Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).Diabetes Care2002https://conductscience.org/library/papers/11815505PubMed
311009049Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart.Eur J Clin Pharmacol2000https://conductscience.org/library/papers/11009049PubMed
412027927Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients.Diabet Med2002https://conductscience.org/library/papers/12027927PubMed
516398567Premixed insulin analogues for the treatment of diabetes mellitus.Drugs2006https://conductscience.org/library/papers/16398567PubMed
615495054Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus.Cochrane Database Syst Rev2004https://conductscience.org/library/papers/15495054PubMed
710359389
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
JAMA1999https://conductscience.org/library/papers/10359389PubMed
816519037Postprandial glucose regulation: new data and new implications.Clin Ther2005https://conductscience.org/library/papers/16519037PubMed
916759299Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.Diabet Med2006https://conductscience.org/library/papers/16759299PubMed
1014749149Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.Clin Ther2003https://conductscience.org/library/papers/14749149PubMed
1115677776Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.Diabetes Care2005https://conductscience.org/library/papers/15677776PubMed
123124685Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study.Ann Intern Med1988https://conductscience.org/library/papers/3124685PubMed
139831300The United Kingdom Prospective Diabetes Study (UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus.Exp Clin Endocrinol Diabetes1998https://conductscience.org/library/papers/9831300PubMed
1412502617Implications of the United kingdom prospective diabetes study.Diabetes Care2003https://conductscience.org/library/papers/12502617PubMed
1514617231Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.Diabetes Obes Metab2003https://conductscience.org/library/papers/14617231PubMed
1618269636Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.Diabetes Obes Metab2008https://conductscience.org/library/papers/18269636PubMed
1716873813
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetes Care2006https://conductscience.org/library/papers/16873813PubMed
1816367881Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.Diabetes Obes Metab2006https://conductscience.org/library/papers/16367881PubMed
1914583174Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin.J Diabetes Complications2003https://conductscience.org/library/papers/14583174PubMed
2015668084Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes.Eur J Intern Med2004https://conductscience.org/library/papers/15668084PubMed

Download CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
26458540Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis.BMC Endocr Disord2015https://conductscience.org/library/papers/26458540PubMed
22818015Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.Drugs2012https://conductscience.org/library/papers/22818015PubMed
22047050The impact of initiating biphasic human insulin 30 therapy in type 2 diabetes patients after failure of oral antidiabetes drugs.Diabetes Technol Ther2012https://conductscience.org/library/papers/22047050PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene
SI6476PubTator's text mininghttps://conductscience.org/library/genes/6476NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19684847

GET https://conductscience.org/api/papers/v1/19684847/authors